153415-45-3

Usage

Uses

Used in Anticancer Applications:
Taxol C is used as an anticancer agent for its ability to promote tubulin assembly and exhibit cytotoxic effects on cancer cells. It has been shown to retain potency similar to Paclitaxel, making it a valuable alternative for cancer treatment.
Used in Pharmaceutical Industry:
Taxol C is used as an impurity in the production of Paclitaxel, a widely used chemotherapy drug. Its presence as an impurity allows for the assessment of the drug's purity and quality, ensuring the safety and efficacy of the final product.

InChI:InChI=1/C46H57NO14/c1-8-9-12-21-33(51)47-35(28-17-13-10-14-18-28)36(52)42(55)59-30-23-46(56)40(60-41(54)29-19-15-11-16-20-29)38-44(7,31(50)22-32-45(38,24-57-32)61-27(4)49)39(53)37(58-26(3)48)34(25(30)2)43(46,5)6/h10-11,13-20,30-32,35-38,40,50,52,56H,8-9,12,21-24H2,1-7H3,(H,47,51)/t30-,31-,32+,35-,36+,37+,38-,40-,44+,45-,46+/m0/s1

Upstream product

• 602319-12-0 3'-N-debenzoyl-3'-N-Troc-7-Troc-paclitaxel 
• 133524-70-6 13-(O-2R-hydroxy-3S-amine-phenylpropionyl)-baccatin III 
• 142-62-1 hexanoic acid 

Downstream Products

• 158948-97-1 2'-OBZ paclitaxel 
• 615563-37-6 C₅₃H₆₁NO₁₅ 
• 615563-34-3 2'-O-benzoyl cephalomannine 
• 876717-13-4 C₅₉H₈₇NO₁₄Si₂ 
• 876717-09-8 C₅₈H₈₅NO₁₄Si₂ 
• 876717-00-9 C₅₆H₈₁NO₁₃Si₂ 
• 876717-05-4 C₅₆H₈₃NO₁₃Si₂ 
• 876716-96-0 C₅₆H₈₃NO₁₃Si₂ 
• 876716-91-5 C₅₀H₆₉NO₁₃Si 
• 876716-86-8 C₅₂H₇₁NO₁₄Si 

Relevant academic research and scientific papers

No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: Scope and limitation of O-N intramolecular acyl and acyloxy migration reactions

Since numerous new taxoids active against multidrug resistant (MDR) tumors have been developed and their poor water-solubility is a very real problem in intravenous administration, we have designed and synthesized a series of novel water-soluble taxoid prodrugs (isotaxoids). These prodrugs, a 2′-O-isoform of taxoids, showed promising results with higher water solubility (0.8-1.1 mg/mL) and proper kinetics for parent drug release by a simple pH-dependent chemical mechanism via O-N intramolecular acyl migration. No additional functional auxiliaries are released during the conversion to parent drugs, which would be an advantage in toxicology and general pharmacology, and the cost for the evaluations of auxiliary units in these fields could be saved in prodrug development. In addition, we demonstrate for the first time the successful application of the O-N intramolecular acyloxy migration reaction in the prodrug design, with the exception of the tert-butyloxycarbonyl group, and that this reaction can be provided with no organic solvent and no side products.